LEE'S PHARMACEUTICAL HOLDINGS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.11 HKD | +3.74% |
|
-4.31% | -27.45% |
| 19/04 | Lee’s Pharmaceutical's 2023 Profit Slumps 67% | MT |
| 26/03 | Lee's Pharmaceutical Holdings Limited Proposes Ordinary Final Dividend for the Year Ended 31 December 2023, Payable on 17 June 2024 | CI |
| Sales 2024 * | 1.28B 163M 13.63B | Sales 2025 * | 1.46B 187M 15.59B | Capitalization | 654M 83.56M 6.97B |
|---|---|---|---|---|---|
| Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | 0.51 x |
| Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 0.45 x |
| P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 1,057 |
| Yield 2024 * |
2.7% | Yield 2025 * |
-
| Free-Float | 31.88% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +3.74% | ||
| 1 week | -4.31% | ||
| Current month | -6.72% | ||
| 1 month | -6.72% | ||
| 3 months | -24.49% | ||
| 6 months | -11.20% | ||
| Current year | -27.45% |
1 week
1.00
1.16
1 month
1.001.26
Current year
1.001.52
1 year
1.001.75
3 years
1.005.13
5 years
1.0011.00
10 years
1.0015.40
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 71 | 01/97/01 | |
Xiao Yi Li
FOU | Founder | 62 | 01/94/01 |
Siu Fong Lee
CHM | Chairman | 67 | 01/97/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
James Gale
BRD | Director/Board Member | 74 | 02/22/02 |
Yau Ching Chan
BRD | Director/Board Member | 61 | 14/02/14 |
Xiao Yi Li
FOU | Founder | 62 | 01/94/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/24/30 | 1.11 | +3.74% | 9 000 |
| 29/24/29 | 1.07 | -0.93% | 155,500 |
| 26/24/26 | 1.08 | -0.92% | 373,500 |
| 25/24/25 | 1.09 | -5.22% | 58,500 |
| 24/24/24 | 1.15 | -0.86% | 90,000 |
Delayed Quote Hong Kong S.E., April 30, 2024 at 01:38 pm IST
More quotes
Lee's Pharmaceutical Holdings Ltd is an investment holding company principally engaged in the development, manufacturing, marketing and sales of pharmaceutical products. The Company operates its business through two segments. The Imported Products segment is engaged in the sale of imported products. Its imported products include Keyan injection, Fipril oral solution and others. The Proprietary Products segment is engaged in the manufacture and sale of self-developed products. Its R&D products include Resilicon Tablets, ADASUVE Inhalation Powder and others. The Company's medicines cover the fields of cardiovascular and infectious diseases, dermatology, oncology, gynecology and ophthalmology. The Company mainly operates its business in mainland China, Hong Kong and Taiwan.
Sector
Pharmaceuticals
Calendar
22/05/2024
- Annual General Meeting
Sell
Buy
Mean consensus
SELL
Number of Analysts
1
Last Close Price
1.11
HKD
Average target price
1
HKD
Spread / Average Target
-9.91%
Chiffre d''affaires - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -27.45% | 80.5M | |
| +33.43% | 664B | |
| +29.29% | 567B | |
| -7.51% | 354B | |
| +18.42% | 330B | |
| +4.59% | 286B | |
| +13.79% | 234B | |
| +4.93% | 199B | |
| -9.78% | 196B | |
| -4.81% | 148B |
- Stock Market
- Equities
- 950 Stock
